: Up over 267% YTD after reporting positive clinical data for its RAS/MAPK pathway-driven cancer treatments.
: Up over 115% YTD (as of April 27) following a recent 21% surge and bullish outlook on its manufacturing turnaround. Analyst "Best Buy" Recommendations for 2026 best buy stocks
: Up over 204% YTD following successful Phase 3 trials for its psoriasis therapy. : Up over 267% YTD after reporting positive